Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake.
BACKGROUND
Recent series of incidental thyroid activity on fluorodeoxyglucose positron emission tomography (FDG-PET) in patients evaluated for nonthyroidal malignancy, which we refer to as a "PEToma," have suggested that such lesions are associated with a significant incidence of primary thyroid cancer.


METHODS
We retrospectively reviewed 6457 FDG-PET scans performed on 4726 patients from May 2004 to March 2007. We reviewed the cases of patients whose PET or computed tomography (CT) radiology reports described PET uptake within the thyroid to identify incidence and malignant potential of PETomas and evaluate their clinical and histopathologic features.


RESULTS
We found that 160 patients (3.4%) had incidental, abnormal FDG uptake in the thyroid gland, 103 of whom had focal uptake (the PEToma group). Of these patients, 50 (48%) underwent further investigations, including ultrasonography in 48, fine-needle aspiration cytology in 38 and computed tomography in 3. Ten patients underwent surgery, and papillary thyroid cancer was identified in 9. The remaining 53 patients with PETomas underwent no further investigation. Interestingly, 5 patients who had focal uptake within the thyroid showed either spontaneous resolution on repeat FDG-PET (self-resolving) or no focal lesion on subsequent ultrasonography (false-positive).


CONCLUSIONS
The incidence of papillary thyroid cancer in the present series is similar to that in the literature. Although some patients will show self-resolving or false-positive focal thyroid uptake on FDG-PET, we believe that, if the patient's clinical status permits, the evaluation of patients with incidental thyroid PEToma should include ultrasonographic confirmation and fine-needle aspiration cytology.
Division of Surgical Oncology, McGill University Health Centre, Montréal, Que., Canada.
Hidefumi
H
Nishimori
Roger
R
Tabah
Marc
M
Hickeson
Jacques
J
How
D000328:Adult; D044963:Biopsy, Fine-Needle; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D033162:Incidental Findings; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014463:Ultrasonography
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
Nucl Med Commun. 2007 May;28(5):373-81
17414887
Otolaryngol Head Neck Surg. 2007 Sep;137(3):400-4
17765765
JAMA. 2006 May 10;295(18):2164-7
16684987
Thyroid. 2006 Feb;16(2):109-42
16420177
Laryngoscope. 2005 Jun;115(6):1074-8
15933524
Am Surg. 2006 Mar;72(3):272-5
16553132
J Nucl Med. 2006 Apr;47(4):609-15
16595494
Nucl Med Commun. 2009 Sep;30(9):742-8
19561553
Ann Surg Oncol. 2007 Nov;14(11):3210-5
17713821
Eur Radiol. 2006 May;16(5):1054-65
16365730
Biomed Pharmacother. 2007 Sep;61(8):488-93
17604940
Thyroid. 2004 Jan;14(1):29-33
15009911
Surgery. 2001 Dec;130(6):941-6
11742321
Anticancer Res. 2005 Mar-Apr;25(2B):1421-6
15865100
Endocrinol Metab Clin North Am. 2000 Mar;29(1):187-203
10732271
Ann Surg Oncol. 2007 Jan;14(1):239-47
17024553
CMAJ. 2007 Nov 20;177(11):1383-4
18025430
Surgery. 2005 Dec;138(6):1166-74; discussion 1174-5
16360405